- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
July 22, 2024Seven Robins Kaplan Attorneys Named to Minnesota Lawyer’s Power 30: Personal Injury List
-
July 18, 2024Emily Niles Named to Law360’s Top Attorneys Under 40
-
July 16, 2024David Martinez Named To 2024 Leaders of Influence: Litigators & Trial Attorneys by Los Angeles Business Journal
-
August 6, 2024Identifying Opportunities: Affirmative Recovery Strategies
-
August 15, 2024Annual Robins Kaplan MAJ Welcome Reception
-
October 20, 2024License Agreement Disputes:
-
July 24, 2024Navigating Copyright Act Section 117 in Software Licensing and Litigation
-
Second QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
July 15, 2024Making The Whole Truth Public
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Reached Settlement Worth Up to $28 Million Against Martin Shkreli and His Former Companies for Alleged Monopolization of Life-Saving Drug Daraprim
Settlement Enjoins Defendants’ Anticompetitive Conduct and Bars Shkreli from the Pharmaceutical Industry for Life
June 17, 2022
BCBSM, Inc. v. Vyera Pharmaceuticals, LLC et al.
On January 31, 2022, as court-appointed interim lead counsel, Robins Kaplan reached a settlement worth up to $28 million on behalf of indirect purchasers alleging that Martin Shkreli and his former companies illegally monopolized the market for Daraprim—a once-affordable, life-saving drug that increased in price by more than 4,000 percent under Shkreli’s leadership.
In March of 2021, Robins Kaplan filed the first—and only—private lawsuit in the country against Martin Shkreli and his former companies Vyera Pharmaceuticals and Phoenixus AG, as well as Vyera’s former CEO Kevin Mulleady. The firm filed suit on behalf of Blue Cross Blue Shield of Minnesota and a proposed class of health plans that purchased or provided reimbursement for Daraprim, the gold-standard treatment for toxoplasmosis, a parasitic infection that can be fatal for people with compromised immune systems, like those with HIV/AIDS. Plaintiffs alleged that defendants endangered vulnerable patients and overcharged health plans by raising the price of Daraprim from $17.50 to $750 per pill while illegally blocking lower-cost generic versions.
The settlement, approved in June of 2022, provides up to $28 million for third-party payors who were allegedly overcharged because of defendants’ scheme, enjoins defendants’ anticompetitive conduct, and bars Shkreli from the pharmaceutical industry for life.
Related Professionals
Ben Steinberg
Partner
Similar Results
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.